TARGETing high-risk childhood cancers.
Megan
M
Scudellari
D002648:Child; D017321:Clinical Trials, Phase I as Topic; D023281:Genomics / Q000379:methods; D006801:Humans; D053612:Janus Kinases / Q000037:antagonists & inhibitors*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism; D008495:Medical Oncology / Q000379:methods / Q000639:trends; D054547:National Cancer Institute (U.S.); D009447:Neuroblastoma / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism; D009570:Nitriles; D012516:Osteosarcoma / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism; D010372:Pediatrics / Q000379:methods / Q000639:trends; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D011720:Pyrazoles / Q000627:therapeutic use*; D011743:Pyrimidines; D014481:United States; D009396:Wilms Tumor / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism
D009570:Nitriles; D011720:Pyrazoles; D011743:Pyrimidines; C540383:ruxolitinib; D053612:Janus Kinases